Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Julie Lai is active.

Publication


Featured researches published by Julie Lai.


Cancer | 2008

Renal and cardiovascular morbidity after partial or radical nephrectomy

David C. Miller; Matthias Schonlau; Mark S. Litwin; Julie Lai; Christopher S. Saigal

To clarify the benefits of nephron‐sparing surgery among patients with early‐stage kidney cancer, the authors compared the frequency of renal and cardiovascular morbidity after partial or radical nephrectomy.


Journal of the National Cancer Institute | 2010

Use of Radical Cystectomy for Patients With Invasive Bladder Cancer

John L. Gore; Mark S. Litwin; Julie Lai; Elizabeth M. Yano; Rodger Madison; Claude Messan Setodji; John L. Adams; Christopher S. Saigal

BACKGROUND Evidence-based guidelines recommend radical cystectomy for patients with muscle-invasive bladder cancer. However, many patients receive alternate therapies, such as chemotherapy or radiation. We examined factors that are associated with the use of radical cystectomy for invasive bladder cancer and compared the survival outcomes of patients with invasive bladder cancer by the treatment they received. METHODS From linked Surveillance, Epidemiology, and End Results-Medicare data, we identified a cohort of 3262 Medicare beneficiaries aged 66 years or older at diagnosis with stage II muscle-invasive bladder cancer from January 1, 1992, through December 31, 2002. We examined the use of radical cystectomy with multilevel multivariable models and survival after diagnosis with the use of instrumental variable analyses. All statistical tests were two-sided. RESULTS A total of 21% of the study subjects underwent radical cystectomy. Older age at diagnosis and higher comorbidity were associated with decreased odds of receiving cystectomy (for those > or = 80 vs 66-69 years old, odds ratio [OR] = 0.10, 95% confidence interval [CI] = 0.07 to 0.14; for Charlson comorbidity index of 3 vs 0-1, OR = 0.25, 95% CI = 0.14 to 0.45). Long travel distance to an available surgeon was associated with decreased odds of receiving cystectomy (for >50 vs 0-4 miles travel distance to an available surgeon, OR = 0.60, 95% CI = 0.37 to 0.98). Overall survival was better for those who underwent cystectomy compared with those who underwent alternative treatments (for chemotherapy and/or radiation vs cystectomy, hazard ratio of death = 1.5, 95% CI = 1.3 to 1.8; for surveillance vs cystectomy, hazard ratio of death = 1.9, 95% CI = 1.6 to 2.3; 5-year adjusted survival: 42.2% [95% CI = 39.1% to 45.4%] for cystectomy; 20.7% [95% CI = 18.7% to 22.8%] for chemotherapy and/or radiation; 14.5% [95% CI = 13.0% to 16.2%] for surveillance). CONCLUSIONS Guideline-recommended care with radical cystectomy is underused for patients with muscle-invasive bladder cancer. Many bladder cancer patients whose survival outcomes might benefit with surgery are receiving alternative less salubrious treatments.


Cancer | 2009

Mortality increases when radical cystectomy is delayed more than 12 weeks

John L. Gore; Julie Lai; Claude Messan Setodji; Mark S. Litwin; Christopher S. Saigal

Single‐institution series have documented the adverse impact of a 12‐week delay between resection of muscle‐invasive bladder cancer and radical cystectomy. These data are derived from tertiary centers, in which referral populations may confound outcomes. The authors sought to examine the survival impact of a delay in radical cystectomy using nationally representative data.


Cancer | 2009

Mortality Increases When Radical Cystectomy Is Delayed More Than 12 Weeks : Results From a Surveillance, Epidemiology, and End Results-Medicare Analysis

John L. Gore; Julie Lai; Claude Messan Setodji; Mark S. Litwin; Christopher S. Saigal

Single‐institution series have documented the adverse impact of a 12‐week delay between resection of muscle‐invasive bladder cancer and radical cystectomy. These data are derived from tertiary centers, in which referral populations may confound outcomes. The authors sought to examine the survival impact of a delay in radical cystectomy using nationally representative data.


Cancer | 2011

Compliance with guidelines for patients with bladder cancer: variation in the delivery of care.

Karim Chamie; Christopher S. Saigal; Julie Lai; Jan M. Hanley; Claude Messan Setodji; Badrinath R. Konety; Mark S. Litwin

Clinical practice guidelines for the management of patients with bladder cancer encompass strategies that minimize morbidity and improve survival. In the current study, the authors sought to characterize practice patterns in patients with high‐grade non–muscle‐invasive bladder cancer in relation to established guidelines.


Cancer | 2013

Recurrence of high‐risk bladder cancer: A population‐based analysis

Karim Chamie; Mark S. Litwin; Jeffrey C. Bassett; Timothy J. Daskivich; Julie Lai; Jan M. Hanley; Badrinath R. Konety; Christopher S. Saigal

Patients with bladder cancer are apt to develop multiple recurrences that require intervention. The recurrence, progression, and bladder cancer–related mortality rates were examined in a cohort of individuals with high‐grade non–muscle‐invasive bladder cancer.


Cancer | 2013

Overall Survival Advantage with Partial Nephrectomy: A Bias of Observational Data?

Brian Shuch; Janet M. Hanley; Julie Lai; Srinivas Vourganti; Simon P. Kim; Claude Messan Setodji; Andrew W. Dick; Wong Ho Chow; Chris Saigal

Partial nephrectomy (PN) and radical nephrectomy (RN) are standard treatments for a small renal mass. Retrospective studies suggest an overall survival (OS) advantage, however a randomized phase 3 trial suggests otherwise. The effects of both surgical modalities on OS were evaluated compared with controls.


Cancer | 2013

Recurrence of high-risk bladder cancer

Karim Chamie; Mark S. Litwin; Jeffrey C. Bassett; Timothy J. Daskivich; Julie Lai; Jan M. Hanley; Badrinath R. Konety; Christopher S. Saigal

Patients with bladder cancer are apt to develop multiple recurrences that require intervention. The recurrence, progression, and bladder cancer–related mortality rates were examined in a cohort of individuals with high‐grade non–muscle‐invasive bladder cancer.


Cancer | 2012

Quality of care in patients with bladder cancer: A case report?

Karim Chamie; Christopher S. Saigal; Julie Lai; Jan M. Hanley; Claude Messan Setodji; Badrinath R. Konety; Mark S. Litwin

Although there is level I evidence demonstrating the superiority of intravesical therapy in patients with bladder cancer, surveillance strategies are primarily founded on expert opinion. The authors examined compliance with surveillance and treatment strategies and the pursuant impact on survival in patients with high‐grade disease.


The Journal of Urology | 2010

Compliance With Antibiotic Prophylaxis in Children With Vesicoureteral Reflux: Results From a National Pharmacy Claims Database

Hillary L. Copp; Caleb P. Nelson; Linda D. Shortliffe; Julie Lai; Christopher S. Saigal; William A. Kennedy

PURPOSE Antibiotic prophylaxis is commonly used for medical management of vesicoureteral reflux. Little information exists on compliance with antibiotic prophylaxis in patients with vesicoureteral reflux. MATERIALS AND METHODS We queried the i3 Innovus (Ingenix) pharmacy claims 2002 to 2007 database for patients 18 years old or younger with vesicoureteral reflux (ICD-9 code 593.7 plus claim for cystogram) and analyzed those with at least 1 year of followup data. Criteria for management with antibiotic prophylaxis were 2 or more 30-day supplies of antibiotic prescriptions, or 4 or more 14-day supplies of prescriptions if the antibiotic was a penicillin or cephalosporin. Antibiotic prophylaxis compliance was determined using a medication possession ratio, an estimate of the proportion of time that patients have a prescribed drug available for use. Compliance was established as a medication possession ratio of 80% or greater, meaning coverage with antibiotic prophylaxis for 80% of the year or more. RESULTS Of 9,496 patients with vesicoureteral reflux 5,342 (56.3%) were treated with antibiotic prophylaxis. Most patients were female (81%) and 5 years old or younger (79%). Trimethoprims/sulfonamides were most commonly prescribed (62%) and antiseptics were next (24%). Of patients prescribed antibiotic prophylaxis 40% were compliant. Compliance was lower for 6 to 10-year-olds (OR 0.71, 95% CI 0.61-0.83) and 11 to 18-year-olds (OR 0.56, 95% CI 0.41-0.79) compared to younger children (5 years or less). Increased compliance was associated with 1 or more hospitalizations (OR 1.70, 95% CI 1.48-1.97) and 1 or more urologist visits (OR 1.41, 95% CI 1.25-1.58). CONCLUSIONS Among patients with vesicoureteral reflux who are prescribed prophylactic antibiotics 40% are compliant with treatment. Young age, frequent hospitalization and specialist visits are associated with compliance. This knowledge may help to develop effective interventions to improve compliance and underscores the importance of reporting compliance in clinical studies evaluating the usefulness of antibiotic prophylaxis in vesicoureteral reflux management.

Collaboration


Dive into the Julie Lai's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mark S. Litwin

University of California

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Karim Chamie

University of California

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

John L. Gore

University of Washington

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge